PLURI INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.27 USD | +2.96% |
|
+5.20% | +35.25% |
| May. 09 | Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
| May. 02 | Pluri Inc. Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment | CI |
Presenter SpeechDana Rubin (Executives)Welcome to Pluristem Investor and Analyst Call. I'm Dan...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Calendar
2024-05-20
- Biomed Israel Conference
| 1st Jan change | Capi. | |
|---|---|---|
| +35.25% | 32.82M | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
- Stock Market
- Equities
- PLUR Stock
- News Pluri Inc.
- Transcript : European Investment Bank, Pluristem Therapeutics Inc. - Shareholder/Analyst Call
